Review Article

Advanced Neuromonitoring and Imaging in Pediatric Traumatic Brain Injury

Stuart H. Friess,1 Todd J. Kilbaugh,2 and Jimmy W. Huh3

1 Department of Anesthesiology and Critical Care, Children’s Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Critical Care Office 7C10, 7 South Tower, Philadelphia, PA 19104, USA
2 Department of Anesthesiology and Critical Care, Children’s Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Critical Care Office 7C08, 7 South Tower, Philadelphia, PA 19104, USA
3 Department of Anesthesiology and Critical Care, Children’s Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Critical Care Office 7C06, 7 South Tower, Philadelphia, PA 19104, USA

Correspondence should be addressed to Jimmy W. Huh, huh@email.chop.edu

Received 3 December 2011; Accepted 22 March 2012

Academic Editor: Anthony A. Figaji

Copyright © 2012 Stuart H. Friess et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

While the cornerstone of monitoring following severe pediatric traumatic brain injury is serial neurologic examinations, vital signs, and intracranial pressure monitoring, additional techniques may provide useful insight into early detection of evolving brain injury. This paper provides an overview of recent advances in neuromonitoring, neuroimaging, and biomarker analysis of pediatric patients following traumatic brain injury.

1. Introduction

Pediatric traumatic brain injury (TBI) remains one of the leading causes of acquired disability and death, with the highest combined rates of TBI-related emergency room visits, hospitalizations, and deaths occurring in the youngest children [1]. Monitoring intracranial pressure (ICP) and cerebral perfusion pressure (CPP), repeat neurological assessments, CT scanning, and vital signs are considered the standard part of care following severe pediatric TBI. However, these assessments may not be sufficient to detect subtle and early secondary insults to the brain, such as ischemia, cerebral cytotoxic or vasogenic edema, and metabolic crisis. With the advent of newer methods of neuromonitoring, neuroimaging, and biomarker development, the concept of advanced neuromonitoring in neurocritical care has evolved in adults following severe TBI and is beginning to be explored in children. In this paper, we will discuss the role of advanced neuromonitoring in children following TBI.

2. Materials and Methods

We performed an extensive review of the medical literature regarding advanced neuromonitoring in children following TBI utilizing Pubmed. Search terms included “pediatric,” “child,” “neonate,” “brain,” “traumatic brain injury,” “multimodality,” “monitoring,” “brain oxygen,” “licox,” “jugular venous saturation,” “microdialysis,” “transcranial doppler,” “neuroimaging,” “diffusion weighted imaging,” “susceptibility weighted imaging,” “diffusion tensor imaging,” “magnetic resonance spectroscopy,” “biospecimen,” “biomarker,” “common data elements,” “S100B,” “neuron specific enolase,” “myelin basic protein,” and “glial fibrillary acidic protein,” and the period of search was from 1987 to 2011. The authors are pediatric neurocritical care specialists and have extensive clinical experience caring for pediatric patients with TBI and research experience in clinical pediatric TBI and experimental animal models of pediatric TBI.
3. Results and Discussion

3.1. Neuromonitoring following Severe TBI in Children

3.1.1. Brain Tissue Oxygen Monitoring. One of the primary management goals of the severely head injured child is to minimize secondary injury. One of the leading causes of secondary injury is cerebral ischemia and hypoxia [2]. Detecting cerebral ischemia with real-time continuous monitoring has proven to be elusive. Adherence to ICP- and CPP-driven management protocols does not guarantee the avoidance of cerebral ischemia or hypoxia [3, 4]. Cerebral blood (CBF) flow threshold for cerebral ischemia in the nontraumatized brain has been reported at 18 mL/100 g/min, and, when CBF falls below 10 mL/100 g/min, cerebral infarction occurs [5, 6]. In TBI, it appears the relationship between CBF and brain metabolism is much more complex. Injured tissues may have reduced metabolic needs due to cellular injury and/or mitochondrial dysfunction in which case lower CBF levels may be appropriate or tissues may be hypermetabolic and normal CBF levels may still result in secondary injury. The ability to measure adequacy of brain oxygen delivery and utilization can assist the clinician in managing the severe pediatric TBI patient to minimize the magnitude of secondary injury. The two most common methods utilized to assess brain oxygenation are brain tissue oxygen tension and jugular venous saturation monitoring, each with various strengths and weaknesses.

3.1.2. Brain Tissue Oxygen Tension Monitoring. Brain tissue oxygen tension (PbtO2) monitoring has been utilized by clinicians to guide medical management of both adult and pediatric severely head injured patients. The most commonly used commercially available system is the Licox system (Licox, Integra Life Sciences, Plainsboro, NJ). A polarographic electrode catheter is inserted into the brain parenchyma of the region of interest using a specially designed bolt system. Oxygen diffuses across the catheter membrane and generates a voltage which is proportional to the amount of oxygen at the electrode site. The voltage/oxygen relationship is temperature dependent, and brain parenchymal temperature must be continuously monitored at the electrode site for accurate PbtO2 measurements. A combined oxygen electrode and temperature probe has been developed to reduce the number of ports required in the bolt system [7]. The probe surface area is approximately 1–15 mm², so that information obtained represents only a very small region of brain parenchyma. This emphasizes the need for confirmation of probe location. Typically after insertion, an oxygen challenge is performed, inspired fraction of oxygen is temporarily increased to 100%, and a subsequent rise in PbtO2 should be observed [4, 8]. Computed tomography (CT) of the head can also be performed to assess probe location, but this need must be weighed with the risk of repeated radiation exposure to the pediatric patient [9].

What the PbtO2 value physiologically represents is not completely clear and is still under investigation. In clinical studies, PbtO2 has been observed to vary with arterial oxygen tension as well as factors that affect CBF (such as arterial CO2 and cerebral perfusion pressure) [10–14]. Most likely, PbtO2 reflects the accumulation of oxygen in the brain parenchyma which is directly influenced by three factors: oxygen delivery, oxygen diffusion characteristics of the region of interest, and oxygen utilization by the brain tissue. Clinical studies have yet to establish normal and threshold values of PbtO2 for adults or children. Extrapolating from animal studies, normal PbtO2 values of 20–30 mm Hg are consistent with what has been observed in regions of uninjured brain clinically [15–17]. A threshold of 10 mm Hg has been associated with ischemic CBF levels, mitochondrial dysfunction, and derangements in cerebral metabolism as measured by microdialysis [6]. A persistent PbtO2 value of 0 mm Hg has been associated with brain death in several case series of both adults and children [18, 19]. PbtO2 values in the 10–20 mm Hg range may represent brain tissue at risk for secondary injury and may prompt the clinician to intervene.

The association of PbtO2 < 10 mm Hg and poor outcome in TBI has been well documented in adults, but it remains unclear if PbtO2-directed management improves outcome [20–23]. Several adult studies have demonstrated improved outcomes following PbtO2-directed therapies compared to historical controls [24–26]. The first reported use of PbtO2-monitoring in children with TBI was a case series of six children reported in 2006 [27]. Since then there have been multiple reports of its use in pediatric TBI, but unfortunately it remains unclear if PbtO2-directed therapy improves outcome [3, 28, 29]. Some of the challenges in attempting to study the efficacy of PbtO2-monitoring include patient population and heterogeneity, the Hawthorne effect when using historical controls, and variations in interventions utilized in response to low PbtO2. Several reports on interventions to increase PbtO2 in children with TBI have recently been published [10, 30]. The effects of increasing arterial oxygen content and carrying capacity on PbtO2 have been evaluated in children with severe TBI [30]. Blood transfusions were observed to transiently increase PbtO2 in 17 children, but PbtO2 returned to baseline within 24 hrs. Normobaric hyperoxia challenges for 15 minutes in 28 children were observed to increase PbtO2, and a more robust response was observed to be associated with poorer outcome [10], but it remains unknown if normobaric hyperoxia should be instituted due to the concerns that an abundance of oxygen may result in increased free radical production and worsening secondary injury [31]. Due to the paucity of strong evidence for PbtO2 monitoring in pediatric TBI, the most recent consensus pediatric TBI guidelines could only make a level III recommendation to consider maintaining a PbtO2 ≥ 10 mm Hg if PbtO2 is used [32]. In summary, interpretation of PbtO2 monitoring in TBI remains complex, and effective and efficacious PbtO2-driven management protocols have yet to be established.

3.1.3. Jugular Venous Saturation Monitoring. Jugular venous saturation monitoring (SjvO2) is another method utilized to detect secondary insults following severe TBI. A catheter is inserted retrogradely to the jugular venous bulb. Catheter placement is confirmed with skull radiograph, with proper positioning demonstrating the catheter tip above the level of C1 [33]. Measurement can be obtained by analysis of
blood samples or by utilizing a fiberoptic catheter to calculate jugular venous oxygen saturation. The incidence of complications associated with SjvO2 monitoring is low but can include bleeding, unintentional arterial puncture, thrombus formation, and infection.

SjvO2 monitoring measures the balance between oxygen supply and demand. Factors affecting oxygen supply include oxygen carrying capacity, arterial oxygen content, oxygen-hemoglobin dissociation at the capillary level and CBF. Oxygen demand is primarily influenced by cerebral metabolic rate of oxygen (CMRO2). Increases in SjvO2 may reflect rises in CBF, reduced diffusion of oxygen into the tissues, or reduced CMRO2. Similarly, decreases in SjvO2 may be the result of cerebral hypoperfusion, decreased arterial oxygen content or carrying capacity, or increased CMRO2. The normal accepted range for SjvO2 in adults is 50–75%, but consensus thresholds for children have not been established. SjvO2 values below 50% in adult TBI patients have been associated with poor outcome [34], while SjvO2 values above 75% have also been observed to have a negative effect on outcome [35].

The pediatric literature for the use of SjvO2 monitoring in children with TBI is quite limited. Pérez et al. reported their experience with 27 children with severe TBI who underwent SjvO2 monitoring [36]. They observed a significant association of two or more episodes of SjvO2 below 50% with poor outcome. However, SjvO2 values greater than 70% were not associated with poor outcome. There are several challenges and limitations to SjvO2 monitoring. Catheter location may vary with head positioning, catheter size may impede its use in younger children, and the development of thrombi can require frequent recalibration. In summary, the pediatric experience with SjvO2 monitoring is limited, normal ranges and SjvO2 thresholds for children have yet to be established and similar to PbtO2 monitoring, and the efficacy of SjvO2 driven management protocols has not been established.

3.1.4. Cerebral Microdialysis. Cerebral microdialysis is a neuromonitoring technique which has primarily been utilized as an invaluable research tool but holds potential to improve the care of the pediatric TBI patient. The technique involves the insertion of a semipermeable membrane tipped catheter into the brain parenchyma. The catheter is then infused with a dialysate at a low continuous rate (typically 1 microliter/min). Small molecules diffuse across the semipermeable membrane from the brain interstitial fluid into the dialysate. Samples can be collected at desired intervals and analyzed for various substances including markers of cell metabolism (lactate, pyruvate, glucose), neurotransmitters (glutamate), or markers of tissue damage (glycerol). The catheter membranes can have various molecular size cutoffs ranging from 20 to 100 kDa. Normal values for several small molecules have been established in adults [37]. Small adult studies have observed sustained elevations in the lactate/pyruvate ratios in pericontusional brain tissue [38]. Elevated brain tissue glycerol levels have also been observed to be associated with poor outcome following severe TBI in adults [39, 40]. A consensus published on microdialysis in adults recommended the use of lactate/pyruvate ratios, glucose, glycerol, and glutamate as markers for the detection of ischemia following TBI [41].

The first use of microdialysis in children with TBI was a case series of nine children in 2002 and focused on the levels of neurotransmitter amino acids (glutamate) as well as nonneurotransmitter amino acids (threonine, tryptophan, lysine, and tyrosine) [42]. Although a small sample size, the authors reported differences in the levels of excitatory neurotransmitters compared to previous reports in adults. This observation highlights the need to explore whether the changes in brain development (such as ongoing myelination) may result in variations in normal ranges and critical thresholds of microdialysis in pediatric TBI compared to adults. In summary, cerebral microdialysis is an exciting research tool which has not yet demonstrated proven benefit in the management of children with severe TBI.

3.1.5. Transcranial Doppler Ultrasonography. Transcranial doppler ultrasonography (TCD) is a bedside test utilized to measure cerebral blood flow velocity typically of the middle cerebral artery. Accuracy of the method can be user dependent, and interobserver reliability can be variable. Cerebral blood flow velocities vary with age, and these changes correlate well with age-dependent changes in CBF [43]. TCD has been utilized as a noninvasive method to estimate CPP and ICP. Utilizing a pulsatility index (PI) under the assumption of stable blood pressure and arterial CO2 content, strong correlations have been observed between PI and elevations in ICP [44–47]. While pediatric TBI experience with PI is not as robust, several recent studies of 34 children with severe TBI revealed a poor correlation of between PI and ICP [48, 49]. TCD can also be used to diagnose cerebral vasospasm which appears to be more common in adult TBI compared to children [49–51].

More recently, TCD has been utilized to evaluate the presence or absence of pressure autoregulation (AR). Cerebral pressure autoregulation is the physiologic response in which the diameter of cerebral blood vessels varies with changes in systemic blood pressure to ensure a constant CBF. As mean arterial pressure (MAP) rises, cerebral blood vessels (typically the arterioles) constrict, and, as mean arterial pressure decreases, cerebral blood vessels dilate. This pressure reactivity is thought to remain intact over a range of MAP from 50 to 150 mm Hg in the adult uninjured brain [52]. An autoregulation index (ARI) has been developed to measure if the autoregulation response is intact by the following equation: ARI = %ΔeCVR/%ΔMAP, where the estimated cerebrovascular resistance (eCVR) is calculated by the ratio of MAP to cerebral blood flow velocity measured by TCD. An ARI value ≥ 0.4 is typically considered intact autoregulation. Autoregulation has been observed to be impaired in up to two-thirds of adults and 40% of children with severe TBI [53–56]. Impairment in autoregulation has been observed to be associated with poor outcome in adult and pediatric TBI patients, but it remains unclear if impaired autoregulation is an independent risk factor for poor outcome [57–59].
3.2. Neuroimaging following TBI in Children

3.2.1. Diffusion Weighted Imaging. While CT scanning may still be the fastest way to evaluate for acute life-threatening intracranial emergencies following pediatric TBI, there has been a tremendous advancement in different MRI techniques to better characterize specific details of the injured brain. Importantly, these different MRI modes detect aspects of TBI that may not be detected by CT or conventional MRI. One of these MRI techniques is diffusion weighted imaging (DWI). Images on DWI are sensitive to differences in the diffusion rate of water molecules and can detect vasogenic and cytotoxic edema. Increased diffusion is thought to occur with vasogenic edema due to increased water in the extracellular space where there is increased mobility, while restricted diffusion due to decreased water movement in the intracellular space is thought to be due to cytotoxic edema [60].

DWI also can quantify water mobility by determining apparent diffusion coefficient (ADC) values, a measure of random water motion limited by cellular composition. ADC measurements are useful in detecting diffuse axonal injury (DAI) in pediatric TBI patients. Before DWI, it was difficult to detect axonal ischemia or damage in the pediatric brain due to the relatively high water content of the developing white matter tracts. DWI allows improved differentiation between the uninjured immature brain and injured area because the immature white matter tracts have less water restriction than mature brain or hyperintense ADC values compared to the adult brain, while injured brain regions usually have increased water restriction or hypointense ADC values relative to the uninjured immature brain [61].

While there are numerous studies of DWI and ADC for lesion detection and outcome following TBI in adults, less is known about DWI and ADC in pediatric TBI. In one recent study, ADC values (obtained within 7 days of injury) in the peripheral white matter tracts were significantly reduced in children with severe TBI that had poor outcomes compared to children with severe TBI that had good outcomes at 6–12 months after trauma [62]. Furthermore, acute ADC values in the peripheral white and gray matter regions following pediatric TBI were inversely correlated with long-term (1–4 years) neurocognitive outcomes [63]. DWI has also been shown to allow earlier detection of acute cerebral ischemia than conventional CT or MRI as processes associated with ischemic injury result in greater diffusion restriction [61, 64]. This may be especially important in cases of suspected abusive pediatric TBI or nonaccidental trauma (NAT). Several studies have revealed that DWI and ADC detected lesions earlier and more extensive brain injury, especially ischemic lesions and lesions in the white matter tracts, than conventional MRI or demonstrated lesions when conventional MRI appeared normal in children with suspected NAT [61, 65–71].

3.2.2. Susceptibility Weighted Imaging. In pediatric TBI, hemorrhagic shearing lesions associated with DAI are a very common pathologic entity [72]. Unlike the large hemorrhages seen in contusions, epidural and subdural hematomas, conventional CT or MRI will usually not pick up these small shearing hemorrhagic lesions. Susceptibility weighted imaging (SWI) is a form of MRI that utilizes the paramagnetic properties of blood products (intravascular and extravascular deoxyhemoglobin, methemoglobin, and hemosiderin) based on their magnetic susceptibility effects in order to increase the visibility of microscopic hemorrhages [73, 74]. SWI has been shown to be superior in detecting hemorrhagic DAI after TBI in children compared to conventional MRI [75, 76]. In another study in children with TBI and DAI, the patients with lower initial Glasgow Coma Scale (GCS) or prolonged coma had a significantly increased average number and volume of hemorrhagic DAI lesions [77]. Furthermore, children who had worse outcome at 6–12 months after injury had significantly increased extent of hemorrhagic DAI lesions [77]. Recently, the increased extent of hemorrhagic DAI was associated with worse intelligence quotient (IQ) and neuropsychologic functioning in children and adolescents at 1–4 years after trauma [78].

SWI may also prove valuable in the assessment of children with NAT. In a recent study, the presence of intraparenchymal brain microhemorrhages in infants with NAT using SWI was associated with worse initial GCS and poor outcome at 6 or more months than children without microhemorrhages [79]. Furthermore, the presence of microhemorrhages on SWI combined with evidence of ischemia on DWI was the most predictive of poor outcome while other radiological findings (extra-axial hemorrhages, skull or skeletal fractures) were not [79].

3.2.3. Diffusion Tensor Imaging. Another novel modality in MRI involves the use of diffusion tensor imaging (DTI), which is a more complex form of DWI. DTI takes advantage of the directionality of water diffusion in the human brain and allows analysis of the white matter tracts [80, 81]. Water diffusion is considered isotropic when motion is free and equal in all directions. In the normal brain tissue, there are physical boundaries that restrict water diffusion in the white matter tracts, with greater water mobility parallel to the axons and restriction of mobility perpendicular to the axons. This diffusion restriction is termed fractional anisotropy (FA) or the ratio of anisotropy to isotropy [82]; FA ranges from 0 to 1, where values closer to 0 represent isotropy or increased diffusion, for example, as a result of injury [83]. In contrast, values closer to 1 represent water diffusion more parallel to the white matter tracts in normal brain tissue. Water diffusion by isotropy is also measured by ADC [84, 85]. Although the association between FA and ADC in the white matter tracts are very complex and incompletely understood, in general FA is inversely related to ADC. Typically, higher FA and lower ADC values are associated with intact white matter tracts.

Pediatric DTI studies done within weeks to years after TBI generally reveal reduced FA. In one study, FA was reduced in the corpus callosum (CC) in TBI patients compared to control patients; FA values were also lower with more severe injuries (GCS < 10 and positive MRI findings) than those with milder injuries (GCS > 10 and normal MRI findings) [86]. Another study revealed reduced FA and
increased ADC in the white matter tracts of the TBI group compared to controls [87] and correlated with cognitive and global outcome [88]. Several studies revealed that DTI studies performed at a mean of 3 years after trauma revealed lower FA in the isthmus, genu, body, and splenium of the CC; those that had a higher FA values had better cognitive function and global outcome [89, 90]. Other studies revealed reduced FA following trauma in various white matter tracts [91–93] and associated with working memory and executive deficits [92, 93]. A different study revealed that the initial injury severity, as assessed by GCS, correlated with changes in the FA in the white matter tracts even at a minimum of 1 year after TBI [94]. In contrast, DTI studies obtained within 1 week after mild pediatric TBI had increased FA and decreased ADC suggestive of cytotoxic edema, compared to controls [95–97]. These DTI abnormalities were associated with more emotional distress, postconcussive symptoms and 30-minute delayed recall [95–97].

3.2.4. Magnetic Resonance Spectroscopy. Another neuroimag-ing technique that allows noninvasive analysis of neurochemicals and their metabolites in the brain involves magnetic resonance spectroscopy (MRS). While MRI uses signals from the proton nuclei of water to reconstruct anatomical images, MRS uses the protons located on neurochemicals within brain tissues. Several key brain metabolites measured by MRS include N-acetylaspartate (NAA), an amino acid synthesized in the mitochondria, that is a neuronal and axonal marker that decreases with neuronal dysfunction or loss [98]. Total creatine (Cr) composed of phosphocreatine and its precursor Cr are markers of intact brain energy metabolism. Total choline (Cho) which predominantly consists of phosphoronyl and glycerophosphoryl Cho is a marker for membrane repair or synthesis, demyelination, or inflammation. Lactate is a result of anaerobic glycolysis and/or may be a response to release of glutamate [99]. Glutamate and glutamine are excitatory amino acid neurotransmitters that are released after TBI and may play a major role in neuronal death [100]. Myo-inositol is an organic osmyolite in astrocytes and increases with glial proliferation [101].

Several MRS studies have revealed decreases in NAA ratios suggesting neuronal dysfunction or loss and increased Cho/Cr suggesting DAI not only in areas of visible injury but also in “normal-appearing” brain after pediatric TBI [102–107]. A decrease in NAA in a visibly injured brain is probably caused by the primary impact, while a decrease in NAA in a “normal-appearing” brain may suggest DAI and subsequent Wallerian degeneration [101]. Studies have also revealed increased lactate, myo-inositol, or glutamate/glutamine levels following pediatric TBI [105, 108, 109]. Some of these neurometabolite alterations have been found to be predictive of outcome. Reduced NAA ratios, increased Cho/Cr or lactate or myo-inositol were associated with poor outcomes 6–12 months after injury [105, 108]. Interestingly, increased glutamate/glutamine levels had no correlation with good or bad outcome 6–12 months following pediatric TBI [109]; in part, this may have been due to the fact that most children with poor outcome were evaluated later than those with good outcome, potentially beyond the time frame for peak elevation of these excitatory amino acid neurotransmitters after injury [109].

Additional studies demonstrated that early MRS predicted long-term (1–4 years) outcome after pediatric TBI. One study demonstrated that regional measures of NAA ratios obtained 1-2 weeks after TBI in children were associated with 40% variance in cognitive function obtained 1–4 years after injury [110]. Furthermore, regional NAA ratios were correlated with attention and executive function [110]. Another study found a correlation between right frontal white matter choline/creatine ratio and reaction time [102]. Another study demonstrated that left frontal white matter choline and creatine correlated with parental report of internalizing behavioral problems and medial frontal gray matter creatine and choline correlated with parental report of social competence [103].

While these various advanced MRI modalities can enhance the early evaluation of children following pediatric TBI, the main disadvantages are the need for transport of a critically ill patient to the scanner, the length of time it takes, the findings are representative of only a “fixed” moment in time, and the potential problem of MRI compatibility with certain neuromonitoring devices.

3.3. Biospecimen, Biomarker, and Common Data Elements

3.3.1. Biospecimen and Biomarker. The FDA defines a biomarker as, “a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.” Human biospecimens can come from likely repositories: tissue, cerebral microdialysate, cerebral spinal fluid (CSF), urine, and blood. These biospecimens represent a critical resource of molecular data (genes, proteins, lipids, metabolites, etc.) and form the emerging field of proteomic and metabolomic analyses in pediatric TBI translational medicine. The study of specific biomarkers for proteomic and metabolomics (including the study of lipids) analyses will allow investigators the ability to identify and quantify injury, pinpoint cellular location, decipher molecular mechanisms, and ultimately develop targeted therapeutic interventions. We will not discuss the study of genomic biomarkers in pediatric TBI due to global ethical questions that still need to be further investigated, but genomic analyses in pediatrics deserve hypothesis-driven clinical research and dedicated collaboration that is starting to emerge in adult TBI [111]. In pediatrics, blood is the most common biospecimen used to study specific biomarkers in pediatric TBI due to its relative availability and ease of collection; however, CSF, urine, and microdialysate have all been reported. Some of the most well-studied biomarkers in pediatric TBI are discussed below.

3.3.2. S100 Calcium Binding Protein B (S100B). S100B is the most extensively studied biomarker in pediatric TBI, and while the mechanism of release is still unknown, it is likely that S100B is released by damaged glial cells and may also
be actively secreted by activated glial cells following brain injury [112]. Initial studies examining reference ranges for S100B in children have shown variability with age and sex, confounding its use in children [113, 114]. However, in one pediatric TBI study, peak levels of S100B correlated with 6-month Glasgow Outcomes Scale (GOS) Extended Pediatric Score with a negative predictive value of 97% combined with a positive predictive value of 75% [115]. Additional studies have also shown some correlation with S100B and predictors of outcome after accidental and inflicted pediatric TBI; however, S100B continues to have limitations that hinder its acceptance as an isolated biomarker for prognostication pediatric TBI: it is found, outside the CNS, there is variability in the values depending on the timing of collection and comorbidities including cardiac arrest [113, 116–120]. As with other biomarkers, prognostication of pediatric TBI outcomes may be improved with a panel of biomarkers, or combining with other predictors such as neuroimaging [121].

3.3.3. Neuron-Specific Enolase and Myelin Basic Protein. Neuron-specific enolase (NSE) is released from neurons passively after cellular destruction [122]. NSE can also be detected in neuroendocrine cells and certain tumor cells, as well red blood cells and platelets. Clinical studies investigating levels of NSE as a biomarker after TBI have found that NSE is neither sensitive nor specific for injury severity following TBI [123]. While NSE has not been proven useful at this time as a biomarker for prognostication, it has been valuable to inform molecular mechanisms of injury following brain injury and help direct translational studies to investigate neuroprotective targets for secondary injury. NSE biomarker levels have similar profiles in pediatric inflicted TBI and pediatric hypoxic-ischemic brain injury, but not in pediatric noninflicted TBI, with delayed increase in serum levels suggesting prolonged neuronal death likely due to apoptotic pathways, and the important role that hypoxic-ischemic injury may play in child abuse and cardiopulmonary arrest [113, 124]. Damage to the axon may be measured by myelin basic protein (MBP), a protein that is found throughout the white matter tracts of the CNS. Similar to NSE, delayed increases in MBP were also found after pediatric inflicted TBI and after pediatric hypoxic-ischemic brain injury suggesting prolonged axonal damage.

3.3.4. Glial Fibrillary Acidic Protein. Glial fibrillary acidic protein (GFAP) is an essential cytoskeletal protein of astrocytes. GFAP does not seem to be found outside the central nervous system, and, unlike S100B, when GFAP is found in the CSF or serum, it is likely to be due to cellular damage and not secretion [125]. In one study, GFAP levels in the serum and CSF were elevated in children with severe TBI. In addition, serum GFAP levels on day 1 postinjury correlated with functional outcome at 6 months and those patients treated with therapeutic hypothermia for TBI did not have significantly different levels as compared to those treated with normothermia [126]. Examples of commonly used biomarker blood tests in clinical medicine include troponin and brain natriuretic peptide (BNP) in cardiac disease. Unfortunately, the clinical study of biomarkers for TBI in children are limited and even the most frequently studied biomarkers (S100 calcium binding protein B, neuron-specific enolase, myelin binding protein) are not currently standard measurement for pediatric TBI. While all of these biomarkers have shown some correlation between concentrations and outcomes, they still lack the statistical power to be clinically useful. Cerebral proteomic and metabolomic analyses are emerging fields, and, with advancing biotechnology, new biomarkers are being developed and researchers are using advanced statistical analysis, such as finite element modeling and combining two or more biomarkers with and without collaborating data, such as neurologic imaging to correlate with outcomes. The hope is that these advanced biomarkers in the future will help assess the degree of TBI, tailor therapy, guide rehabilitation, and aid caregivers, and families in difficult decisions.

3.3.5. Common Data Elements (CDEs) for Biospecimens. Pediatric TBI is a global problem, with the World Health Organization predicting that by the year 2020 TBI will be the most common cause of death in children. Coordinated research and strength of evidence-based medicine require standardization of definitions and data elements to compare findings across studies and facilitate data sharing amongst institutions [127]. This has recently been extended to include recommendations for pediatric patients, including recommendations from an expert panel for best practice guidelines to standardize the quality and accessibility of biospecimens for pediatric TBI [128]. While there are no specific recommendations regarding specific biomarkers, this expert panel does outline guidelines that will allow for consistency across studies to develop a minimal set of measures and direction for additional biospecimen collection for hypothesis-driven studies. Core CDE (minimum) recommendations include the collection of an acute (<24 h postinjury) serum sample for proteomic and metabolomics analyses [128]. Supplemental CDE (greater depth and breadth of exploration) recommendations focus on serial collection of serum and CSF samples which will allow for study of injury progression and trajectory, including identification of evolving molecular derangement and eventual study of molecular-targeted interventions dependent on the temporal cascade of secondary injury. More controversial is an extended CDE (emerging study in pediatrics requiring validation) recommendation for cerebral microdialysis as a data element [128]. Cerebral microdialysis as described in previous sections has not been universally adopted in pediatric TBI; however, microdialysis is extensively used in adult patients as a measure of cerebral metabolism and cerebral bioenergetic dysfunction. Further recommendations focus on the specifics of biospecimen collection, processing, documentation, and storage. In the emerging field of cerebral biomarkers of injury, a common vernacular and scientifically based analyses will allow clinicians to pool resources and standardize the approach to study and intervene for our most at-risk patients, pediatric severe TBI.
4. Conclusion
Neurorouting technology is at an “infant” stage in pediatric TBI. While further studies are clearly needed to determine whether these modalities and advancement in technology with noninvasive monitors will allow early and reliable recognition of reversible secondary brain insults, the ultimate question is whether these new modalities will aid in treatment strategies that will positively affect outcome.

References
[1] V. G. Coronado, L. Xu, S. V. Basavaraju et al., “Surveillance for traumatic brain injury-related deaths—United States, 1997–2007,” Morbidity and Mortality Weekly Report, vol. 60, no. 5, pp. 1–36, 2011.
[2] P. M. Kochanek, R. S. Clark, R. A. Ruppel et al., “Biochemical, cellular, and molecular mechanisms in the evolution of secondary damage after severe traumatic brain injury in infants and children: lessons learned from the bedside,” Pediatric Critical Care Medicine, vol. 1, no. 1, pp. 4–19, 2000.
[3] A. A. Figaji, A. G. Fieggen, A. C. Argent, P. D. Leroux, and J. C. Peter, “Does adherence to treatment targets in children with severe traumatic brain injury avoid brain hypoxia? A brain tissue oxygenation study,” Neurosurgery, vol. 63, no. 1, pp. 83–91, 2008.
[4] M. F. Stiefel, J. D. Udootuk, A. M. Spiotta et al., “Conventional neurocritical care and cerebral oxygenation after traumatic brain injury,” Journal of Neurology Neurosurgery and Psychiatry, vol. 105, no. 4, pp. 568–575, 2006.
[5] J. Astrup, B. K. Siejo, and L. Symon, “Thresholds in cerebral ischemia—the ischemic penumbra,” Stroke, vol. 12, no. 6, pp. 723–725, 1981.
[6] R. S. Marshall, “The functional relevance of cerebral hemodynamics: why blood flow matters to the injured and recovering brain,” Current Opinion in Neurology, vol. 17, no. 6, pp. 705–709, 2004.
[7] C. Stewart, J. Haitsma, Z. Zador et al., “The new licox combined brain tissue oxygen and brain temperature monitor: assessment of in vitro accuracy and clinical experience in severe traumatic brain injury,” Neurosurgery, vol. 63, no. 6, pp. 1159–1164, 2008.
[8] A. A. Adamides, D. J. Cooper, F. L. Rosenfeldt et al., “Focal cerebral oxygenation and neurological outcome with or without brain tissue oxygen-guided therapy in patients with traumatic brain injury,” Acta Neurochirurgica Supplement, vol. 151, no. 11, pp. 1399–1409, 2009.
[9] B. Furlow, “Radiation protection in pediatric imaging,” Radiologic Technology, vol. 82, no. 5, pp. 421–439, 2011.
[10] A. A. Figaji, E. Zwane, A. G. Fieggen, A. C. Argent, P. D. Le Roux, and J. C. Peter, “The effect of increased inspired fraction of oxygen on brain tissue oxygen tension in children with severe traumatic brain injury,” Neurocritical Care, vol. 12, no. 3, pp. 430–437, 2010.
[11] G. Rosenthal, J. C. Hemphill III, M. Sorani et al., “Brain tissue oxygen tension is more indicative of oxygen diffusion than oxygen delivery and metabolism in patients with traumatic brain injury,” Critical Care Medicine, vol. 36, no. 6, pp. 1917–1924, 2008.
[12] A. K. Gupta, P. J. Hutchinson, P. Al-Rawi et al., “Measuring brain tissue oxygenation compared with jugular venous oxygen saturation for monitoring cerebral oxygenation after traumatic brain injury,” Anesthesia and Analgesia, vol. 88, no. 3, pp. 549–553, 1999.
[13] R. Imberti, G. Bellinzona, and M. Langer, “Cerebral tissue PO2 and SvO2 changes during moderate hyperventilation in patients with severe traumatic brain injury,” Journal of Neurosurgery, vol. 96, no. 1, pp. 97–102, 2002.
[14] P. Bruzzone, R. Dionigi, G. Bellinzona, R. Imberti, and N. Stocchetti, “Effects of cerebral perfusion pressure on brain tissue PO2 in patients with severe head injury,” Acta Neurochirurgica Supplement, vol. 1998, no. 71, pp. 111–113, 1998.
[15] W. E. Hoffman, F. T. Charbel, G. Gonzalez-Portillo, and J. I. Ausman, “Measurement of ischemia by changes in tissue oxygen, carbon dioxide, and pH,” Surgical Neurology, vol. 51, no. 6, pp. 654–658, 1999.
[16] C. D. Kurfth, J. C. McCann, J. Wu, L. Miles, and A. W. Loepke, “Cerebral oxygen saturation-time threshold for hypoxic-ischemic injury in piglets,” Anesthesia and Analgesia, vol. 108, no. 4, pp. 1268–1277, 2009.
[17] A. I. Maas, W. Fleckenstein, D. A. de Jong, and H. van Sanderink, “Monitoring cerebral oxygenation: experimental studies and preliminary clinical results of continuous monitoring of cerebrospinal fluid and brain tissue oxygen tension,” Acta Neurochirurgica Supplement, vol. 59, pp. 50–57, 1993.
[18] A. A. Figaji and S. J. Kent, “Brain tissue oxygenation in children diagnosed with brain death,” Neurocritical Care, vol. 12, no. 1, pp. 56–61, 2010.
[19] M. L. Smith, G. J. Counelis, E. Maloney-Wilensky, M. F. Stiefel, K. Donley, and P. D. LeRoux, “Brain tissue oxygen tension in clinical brain death: a case series,” Neurological Research, vol. 29, no. 7, pp. 755–759, 2007.
[20] A. A. Figaji, E. Zwane, C. Thompson et al., “Brain tissue oxygen tension monitoring in pediatric severe traumatic brain injury. Part 1: relationship with outcome,” Child’s Nervous System, vol. 25, no. 10, pp. 1325–1333, 2009.
[21] E. Maloney-Wilensky, V. Gracias, A. Itkin et al., “Brain tissue oxygen and outcome after severe traumatic brain injury: a systematic review,” Critical Care Medicine, vol. 37, no. 6, pp. 2057–2063, 2009.
[22] P. K. Narotam, S. C. Burjonrappa, S. C. Raynor, M. Rao, and C. Tylon, “Cerebral oxygenation in major pediatric trauma: its relevance to trauma severity and outcome,” Journal of Pediatric Surgery, vol. 41, no. 3, pp. 505–513, 2006.
[23] A. B. Valadka, S. P. Gopinath, C. F. Contant, M. Uzura, and C. S. Robertson, “Relationship of brain tissue PO2 to outcome after severe head injury,” Critical Care Medicine, vol. 26, no. 9, pp. 1576–1581, 1998.
[24] M. F. Stiefel, A. Spiotta, V. H. Gracias et al., “Reduced mortality rate in patients with severe traumatic brain injury treated with brain tissue oxygen monitoring,” Journal of Neurosurgery, vol. 103, no. 3, pp. 805–811, 2005.
[25] P. K. Narotam, J. F. Morrison, and N. Nathoo, “Brain tissue oxygen monitoring in traumatic brain injury and major trauma: outcome analysis of a brain tissue oxygen-directed therapy,” Journal of Neurosurgery, vol. 111, no. 4, pp. 672–682, 2009.
[26] J. Meixensberger, M. Jaeger, A. Vath, J. Dings, E. Kunze, and K. Roosn, “Brain tissue oxygen guided treatment supplementing ICP/CPP therapy after traumatic brain injury,” Journal of Neurology Neurosurgery Psychiatry, vol. 74, no. 6, pp. 760–764, 2003.
[27] M. F. Stiefel, J. D. Udootuk, P. B. Storm et al., “Brain tissue oxygen monitoring in pediatric patients with severe traumatic brain injury,” Journal of Neurosurgery, vol. 105, Supplement 4, pp. 281–286, 2006.
[28] A. A. Figaji, E. Zwane, A. G. Fieggen et al., “Pressure autoregulation, intracranial pressure, and brain tissue oxygenation in children with severe traumatic brain injury: clinical article,” *Journal of Neurosurgery*, vol. 4, no. 5, pp. 420–428, 2009.

[29] A. A. Figaji, E. Zwane, C. Thompson et al., “Brain tissue oxygen tension monitoring in pediatric severe traumatic brain injury. Part 2: relationship with clinical, physiological, and treatment factors,” *Child's Nervous System*, vol. 25, no. 10, pp. 1335–1343, 2009.

[30] A. A. Figaji, E. Zwane, M. Kogels et al., “The effect of blood transfusion on brain oxygenation in children with severe traumatic brain injury,” *Pediatric Critical Care Medicine*, vol. 11, no. 3, pp. 325–331, 2010.

[31] M. N. Diringer, “Hyperoxia: good or bad for the injured brain?” *Current Opinion in Critical Care*, vol. 14, no. 2, pp. 167–171, 2008.

[32] P. M. Kochanek, N. Carney, P. D. Adelson et al., “Guidelines for the acute medical management of severe traumatic brain injury in infants, children, and adolescents—second edition,” *Pediatric Critical Care Medicine*, vol. 13, Supplement 1, pp. S1–S2, 2012.

[33] C. S. Macmillan and P. J. Andrews, “Cerebrovenous oxygen saturation monitoring: practical considerations and clinical relevance,” *Intensive Care Medicine*, vol. 26, no. 8, pp. 1028–1036, 2000.

[34] S. L. Bratton, R. M. Chestnut, J. Ghajar et al., “Guidelines for the management of severe traumatic brain injury. X. Brain oxygen monitoring and thresholds,” *Journal of Neurotrauma*, vol. 24, Supplement 1, pp. S65–S70, 2007.

[35] M. Cormio, A. B. Valadka, and C. S. Robertson, “Elevated jugular venous oxygen saturation after severe head injury,” *Journal of Neurosurgery*, vol. 90, no. 1, pp. 9–15, 1999.

[36] A. Pérez, P. G. Minecs, E. J. Schnitzler, G. E. Agosta, S. A. Medina, and C. A. Cirillo, “Jugular venous oxygen saturation or arteriovenous difference of lactate content and outcome in children with severe traumatic brain injury,” *Pediatric Critical Care Medicine*, vol. 4, no. 1, pp. 33–36, 2003.

[37] L. Hillerud, P. M. Vespà, and D. A. Hovda, “Translational neurochemical research in acute human brain injury: the current status and potential future for cerebral microdialysis,” *Journal of Neurotrauma*, vol. 22, no. 1, pp. 3–41, 2005.

[38] P. M. Vespa, K. O’Phelan, D. McArthur et al., “Pericontusional brain tissue exhibits persistent elevation of lactate/pyruvate ratio independent of cerebral perfusion pressure,” *Critical Care Medicine*, vol. 35, no. 4, pp. 1153–1160, 2007.

[39] N. Stahl, P. Mellergard, A. Hallstrom, U. Ungerstedt, and C. H. Nordstrom, “Intracerebral microdialysis and bedside biochemical analysis in patients with fatal traumatic brain lesions,” *Acta Anaesthesiologica Scandinavica*, vol. 45, no. 8, pp. 977–985, 2001.

[40] T. Clausen, O. L. Alves, M. Reinert, E. Doppenberg, A. Zauner, and R. Bullock, “Association between elevated brain tissue glyceral levels and poor outcome following severe traumatic brain injury,” *Journal of Neurosurgery*, vol. 103, no. 2, pp. 233–238, 2005.

[41] B. M. Bellander, E. Cantais, P. Enblad et al., “Consensus meeting on microdialysis in neurointensive care,” *Intensive Care Medicine*, vol. 30, no. 12, pp. 2166–2169, 2004.

[42] C. M. Toliass, D. A. Richards, N. G. Bowery, and S. Sgouros, “Extracellular glutamate in the brains of children with severe head injuries: a pilot microdialysis study,” *Child's Nervous System*, vol. 18, no. 8, pp. 368–374, 2002.

[43] C. Chiron, C. Raynaud, B. Maziere et al., “Changes in regional cerebral blood flow during brain maturation in children and adolescents,” *Journal of Nuclear Medicine*, vol. 33, no. 5, pp. 696–703, 1992.

[44] J. Bellner, B. Romner, P. Reinspru, K. A. Kristiansson, E. Ryding, and L. Brandt, “Transcranial Doppler sonography pulsatility index (PI) reflects intracranial pressure (ICP),” *Surgical Neurology*, vol. 62, no. 1, pp. 45–51, 2004.

[45] J. A. Moreno, E. Mesalles, J. Gener et al., “Evaluating the outcome of severe head injury with transcranial Doppler ultrasonography,” *Neurosurgical Focus*, vol. 8, no. 1, article e8, 2000.

[46] B. Splavski, B. Radanovic, D. Vrankovic et al., “Transcranial Doppler ultrasonography as an early outcome forecaster following severe brain injury,” *British Journal of Neurosurgery*, vol. 20, no. 6, pp. 386–390, 2006.

[47] B. Splavski, B. Radanovic, D. Muzevic et al., “Assessment of intra-cranial pressure after severe traumatic brain injury by transcranial Doppler ultrasonography,” *Brain Injury*, vol. 20, no. 12, pp. 1265–1270, 2006.

[48] P. G. Meyer, S. Ducrocq, T. Rancelbom, G. Orliauet, D. Renier, and P. Carli, “Surgical evacuation of acute subdural hematoma improves cerebral hemodynamics in children: a transcranial Doppler evaluation,” *Child's Nervous System*, vol. 21, no. 2, pp. 133–137, 2005.

[49] A. A. Figaji, E. Zwane, A. G. Fieggen, P. Siesjo, and J. C. Peter, “Transcranial Doppler pulsatility index is not a reliable indicator of intracranial pressure in children with severe traumatic brain injury,” *Surgical Neurology*, vol. 72, no. 4, pp. 389–394, 2009.

[50] N. A. Martin, R. V. Patwardhan, M. J. Alexander et al., “Characterization of cerebral hemodynamic phases following severe head trauma: hyperperfusion, hyperemia, and vasospasm,” *Journal of Neurosurgery*, vol. 87, no. 1, pp. 9–19, 1997.

[51] N. A. Martin, C. Doberstein, C. Zane, M. J. Caron, K. Thomas, and D. P. Becker, “Posttraumatic cerebral arterial spasm: transcranial Doppler ultrasound, cerebral blood flow, and angiographic findings,” *Journal of Neurosurgery*, vol. 77, no. 4, pp. 575–583, 1992.

[52] O. B. Paulson, S. Strandgaard, and L. Edvinsson, “Cerebral autoregulation,” *Cerebrovascular & Brain Metabolism Reviews*, vol. 2, no. 2, pp. 161–192, 1990.

[53] Y. Udomphorn, W. M. Armstead, and M. S. Vavilala, “Cerebral blood flow and autoregulation after pediatric traumatic brain injury,” *Pediatric Neurology*, vol. 38, no. 4, pp. 225–234, 2008.

[54] M. S. Vavilala, L. A. Lee, K. Boddu et al., “Cerebral autoregulation in pediatric traumatic brain injury,” *Pediatric Critical Care Medicine*, vol. 5, no. 3, pp. 257–263, 2004.

[55] J. Sahuquillo, F. Munar, M. Baguena, M. A. Poca, S. Pedraza, and A. Rodriguez-Baeza, “Evaluation of cerebrovascular CO2-reactivity and autoregulation in patients with post-traumatic diffuse brain swelling (diffuse injury III),” *Acta Neurochirurgica Supplementum*, vol. 71, no. 233, pp. 236–1998.

[56] G. J. Bouma, J. P. Muizelaar, K. Bandoh, and A. Marmarou, “Blood pressure and intracranial pressure-volume dynamics in severe head injury: relationship with cerebral blood flow,” *Journal of Neurosurgery*, vol. 77, no. 1, pp. 15–19, 1992.

[57] M. S. Vavilala, S. Muangman, N. Tontisirin et al., “Impaired cerebral autoregulation and 6-month outcome in children with severe traumatic brain injury: preliminary findings,” *Developmental Neuroscience*, vol. 28, no. 4–5, pp. 348–353, 2006.

[58] L. A. Steiner, M. Czosnyka, S. K. Piechnik et al., “Continuous monitoring of cerebrovascular pressure reactiiveness allows
determination of optimal cerebral perfusion pressure in patients with traumatic brain injury,” Critical Care Medicine, vol. 30, no. 4, pp. 733–738, 2002.

[59] R. B. Panerai, V. Kerins, L. Fan, P. M. Yeoman, T. Hope, and D. H. Evans, “Association between dynamic cerebral autoregulation and mortality in severe head injury,” British Journal of Neurosurgery, vol. 18, no. 5, pp. 471–479, 2004.

[60] K. Hergan, P. W. Schaefer, A. G. Sorensen, R. G. Gonzalez, and T. A. Huisman, “Diffusion-weighted MRI in diffuse axonal injury of the brain,” European Radiology, vol. 12, no. 10, pp. 2536–2541, 2002.

[61] D. Y. Suh, P. C. Davis, K. L. Hopkins, N. N. Fajman, and T. B. Mapstone, “Nonaccidental pediatric head injury: diffusion-weighted imaging findings,” Neurosurgery, vol. 49, no. 2, pp. 309–320, 2001.

[62] N. R. Galloway, K. A. Tong, S. Ashwal, U. Oyoyo, and A. Obenaus, “Diffusion-weighted imaging improves outcome prediction in pediatric traumatic brain injury,” Journal of Neurotrauma, vol. 25, no. 10, pp. 1153–1162, 2008.

[63] T. Babikian, K. A. Tong, N. R. Galloway, M. C. Freier-Randall, A. Obenaus, and S. Ashwal, “Diffusion-weighted imaging predicts cognition in pediatric brain injury,” Pediatric Neurology, vol. 41, no. 6, pp. 406–412, 2009.

[64] T. A. Huisman, “Diffusion-weighted imaging: basic concepts and application in cerebral stroke and head trauma,” European Radiology, vol. 13, no. 10, pp. 2283–2297, 2003.

[65] V. Bioussé, D. Y. Suh, N. J. Newman, P. C. Davis, T. Mapstone, and S. R. Lambert, “Diffusion-weighted magnetic resonance imaging in shaken baby syndrome,” American Journal of Ophthalmology, vol. 133, no. 2, pp. 249–255, 2002.

[66] Y. L. Chan, W. C. Chu, G. W. Wong, and D. K. Yeung, “Diffusion-weighted MRI in shaken baby syndrome,” Pediatric Radiology, vol. 33, no. 8, pp. 574–577, 2003.

[67] P. M. Parizel, B. Ceulemans, A. Laridon, O. Ozsarlik, J. W. van Goethem, and P. G. Jorens, “Cortical hypoxic-ischemic brain damage in shaken baby (shaken impact) syndrome: value of diffusion-weighted MRI,” Pediatric Radiology, vol. 33, no. 12, pp. 868–871, 2003.

[68] R. A. Zimmerman, L. T. Bilaniuk, and L. Farina, “Nonaccidental brain trauma in infants: diffusion imaging, contributions to understanding the injury process,” Journal of Neuroradiology, vol. 34, no. 2, pp. 109–114, 2007.

[69] A. M. Kemp, S. Rajaram, M. Mann et al., “What neuroimaging should be performed in children in whom inflicted brain injury (ibi) is suspected? A systematic review,” Clinical Radiology, vol. 64, no. 5, pp. 473–483, 2009.

[70] K. Ajilogba and P. Rao, “Diffusion-weighted imaging of wallerian degeneration in non-accidental head injury,” Pediatric Radiology, vol. 36, no. 12, article 1326, 2006.

[71] A. M. McKinney, L. R. Thompson, C. L. Truwit, S. Velders, A. Karagulle, and A. Kiragu, “Unilateral hypoxic-ischemic injury in young children from abusive head trauma, lacking cranioventricular vascular dissection or cord injury,” Pediatric Radiology, vol. 38, no. 2, pp. 164–174, 2008.

[72] J. A. Blackman, S. A. Rice, J. A. Matsumoto et al., “Brain imaging as a predictor of early functional outcome following traumatic brain injury in children, adolescents, and young adults,” Journal of Head Trauma Rehabilitation, vol. 18, no. 6, pp. 493–503, 2003.

[73] E. M. Haacke, N. Y. Cheng, M. J. House et al., “Imaging iron stores in the brain using magnetic resonance imaging,” Magnetic Resonance Imaging, vol. 23, no. 1, pp. 1–25, 2005.

[74] V. Sehgal, Z. Delproposto, E. M. Haacke et al., “Clinical applications of neuroimaging with susceptibility-weighted imaging,” Journal of Magnetic Resonance Imaging, vol. 22, no. 4, pp. 439–450, 2005.

[75] K. A. Tong, S. Ashwal, B. A. Holshouser et al., “Hemorrhagic shearing lesions in children and adolescents with postramatic diffuse axonal injury: improved detection and initial results,” Radiology, vol. 227, no. 2, pp. 332–339, 2003.

[76] M. H. Beauchamp, M. Ditchfield, F. E. Babel et al., “Detecting traumatic brain lesions in children: CT versus MRI versus susceptibility weighted imaging (SWI),” Journal of Neurotrauma, vol. 28, no. 6, pp. 915–927, 2011.

[77] K. A. Tong, S. Ashwal, B. A. Holshouser et al., “Diffuse axonal injury in children: clinical correlation with hemorrhagic lesions,” Annals of Neurology, vol. 56, no. 1, pp. 36–50, 2004.

[78] T. Babikian, M. C. Freier, K. A. Tong et al., “Susceptibility weighted imaging: neuropsychologic outcome and pediatric head injury,” Pediatric Neurology, vol. 33, no. 3, pp. 184–194, 2005.

[79] C. A. Colbert, B. A. Holshouser, G. S. Aaen et al., “Value of cerebral microhemorrhages detected with susceptibility-weighted MR imaging for prediction of long-term outcome in children with nonaccidental trauma,” Radiology, vol. 256, no. 3, pp. 898–905, 2010.

[80] S. Morì, B. J. Crain, V. P. Chacko, and P. C. van Zijl, “Three-dimensional tracking of axonal projections in the brain by magnetic resonance imaging,” Annals of Neurology, vol. 45, no. 2, pp. 265–269, 1999.

[81] P. McGraw, L. Liang, and J. M. Provenzale, “Evaluation of normal age-related changes in anisotropy during infancy and childhood as shown by diffusion tensor imaging,” American Journal of Roentgenology, vol. 179, no. 6, pp. 1515–1522, 2002.

[82] T. Klingberg, C. J. Vaidya, J. D. Gabrieli, M. E. Moseley, and M. Hedehus, “Myelination and organization of the frontal white matter in children: a diffusion tensor MRI study,” NeuroReport, vol. 10, no. 13, pp. 2817–2821, 1999.

[83] S. J. Suskauer and T. A. Huisman, “Neuroimaging in pediatric traumatic brain injury: current and future predictors of functional outcome,” Developmental Disabilities Research Reviews, vol. 15, no. 2, pp. 117–123, 2009.

[84] P. C. Sundgren, Q. Dong, D. Gómez-Hassan, S. K. Mukherji, P. Maly, and R. Welsh, “Diffusion tensor imaging of the brain: review of clinical applications,” Neuroradiology, vol. 46, no. 5, pp. 339–350, 2004.

[85] K. Arfanakis, V. M. Haughton, J. D. Carew, B. P. Rogers, E. Akpinar, M. Koroglu, and T. Ptak, “Diffusion tensor MRI study,” Journal of Computer Assisted Tomography, vol. 23, no. 4, pp. 439–450, 2005.

[86] E. A. Wilde, E. D. Bigler et al., “Longitudinal changes in the corpus callosum following pediatric traumatic brain injury,” Developmental Neurosciences, vol. 32, no. 5-6, pp. 361–373, 2011.

[87] H. S. Levin, E. A. Wilde, Z. Chu et al., “Diffusion tensor imaging in relation to cognitive and functional outcome of traumatic brain injury in children,” Journal of Head Trauma Rehabilitation, vol. 23, no. 4, pp. 197–208, 2008.

[88] E. A. Wilde, Z. Chu, E. D. Bigler et al., “Diffusion tensor imaging in the corpus callosum in children after moderate to severe traumatic brain injury,” Journal of Neurotrauma, vol. 23, no. 10, pp. 1412–1426, 2006.

[89] L. Ewing-Cobbs, M. R. Prasad, P. Swank et al., “Arrested development and disrupted callosal microstructure following...
pediatric traumatic brain injury: relation to neurobehavioral outcomes,” *Neuroimage*, vol. 42, no. 4, pp. 1305–1315, 2008.

[91] E. A. Wilde, E. D. Bigler, J. M. Haider et al., “Vulnerability of the anterior commissure in moderate to severe pediatric traumatic brain injury,” *Journal of Child Neurology*, vol. 21, no. 9, pp. 769–776, 2006.

[92] J. R. Wozniak, L. Krach, E. Ward et al., “Neurocognitive and neuroimaging correlates of pediatric traumatic brain injury: a diffusion tensor imaging (DTI) study,” *Archives of Clinical Neuropsychology*, vol. 22, no. 5, pp. 555–568, 2007.

[93] B. Kurowski, S. L. Wade, K. M. Cecil, N. C. Walz, W. Yuan, A. Rajagopal et al., “Correlation of diffusion tensor imaging with executive function measures after early childhood traumatic brain injury,” *Journal of Pediatric Rehabilitation Medicine*, vol. 2, no. 4, pp. 273–283, 2009.

[94] W. Yuan, S. K. Holland, V. J. Schmithorst et al., “Diffusion tensor MR imaging reveals persistent white matter alteration after traumatic brain injury experienced during early childhood,” *American Journal of Neuroradiology*, vol. 28, no. 10, pp. 1919–1925, 2007.

[95] E. A. Wilde, S. R. McCauley, J. V. Hunter et al., “Diffusion tensor imaging of acute mild traumatic brain injury in adolescents,” *Neurology*, vol. 70, no. 12, pp. 948–955, 2008.

[96] Z. Chu, E. A. Wilde, J. V. Hunter et al., “Voxel-based analysis of diffusion tensor imaging in mild traumatic brain injury in adolescents,” *American Journal of Neuroradiology*, vol. 31, no. 2, pp. 340–346, 2010.

[97] T. C. Wu, E. A. Wilde, E. D. Bigler et al., “Evaluating the relationship between memory functioning and cingulum bundles in acute mild traumatic brain injury using diffusion tensor imaging,” *Journal of Neurotrauma*, vol. 27, no. 2, pp. 305–307, 2010.

[98] E. R. Danielsen, T. Michaelis, and B. D. Ross, “Three methods of calibration in quantitative proton MR spectroscopy,” *Journal of Magnetic Resonance B*, vol. 106, no. 3, pp. 287–291, 1995.

[99] B. Alessandri, R. Al-Samsam, F. Corwin, P. Fatouros, H. F. Young, and R. M. Bullock, “Acute and late changes in N-acetyl-aspartate following diffuse axonal injury in rats: an MRI spectroscopy and microdialysis study,” *Neurological Research*, vol. 22, no. 7, pp. 703–712, 2000.

[100] R. Bullock, A. Zauner, J. J. Woodward et al., “Factors affecting excitatory amino acid release following severe human head injury,” *Journal of Neurosurgery*, vol. 89, no. 4, pp. 507–518, 1998.

[101] M. R. Garnett, A. M. Blamire, R. G. Corkill, T. A. Cadoux-Hudson, B. Rajagopalan, and P. Styles, “Early proton magnetic resonance spectroscopy in normal-appearing brain correlates with outcome in patients following traumatic brain injury,” *Brain*, vol. 123, no. 10, pp. 2046–2054, 2000.

[102] L. Parry, A. Shores, C. Rae et al., “An investigation of neuronal integrity in severe paediatric traumatic brain injury,” *Child Neuropsychology*, vol. 10, no. 4, pp. 248–261, 2004.

[103] N. C. Walz, K. M. Cecil, S. L. Wade, and L. J. Michaud, “Late proton magnetic resonance spectroscopy following traumatic brain injury during early childhood: relationship with neurobehavioral outcomes,” *Journal of Neurotrauma*, vol. 25, no. 2, pp. 94–103, 2008.

[104] R. A. Yeo, J. P. Phillips, R. E. Jung, A. J. Brown, R. C. Campbell, and W. M. Brooks, “Magnetic resonance spectroscopy detects brain injury and predicts cognitive functioning in children with brain injuries,” *Journal of Neurotrauma*, vol. 23, no. 10, pp. 1427–1435, 2006.

[105] S. Ashwal, B. A. Holshouser, S. K. Shu et al., “Predictive value of proton magnetic resonance spectroscopy in pediatric closed head injury,” *Pediatric Neurology*, vol. 23, no. 2, pp. 114–125, 2000.

[106] J. V. Hunter, R. J. Thornton, Z. J. Wang et al., “Late proton MR spectroscopy in children after traumatic brain injury: correlation with cognitive outcomes,” *American Journal of Neuroradiology*, vol. 26, no. 3, pp. 482–488, 2005.

[107] B. A. Holshouser, K. A. Tong, and S. Ashwal, “Proton MR spectroscopic imaging depicts diffuse axonal injury in children with traumatic brain injury,” *American Journal of Neuroradiology*, vol. 26, no. 5, pp. 1276–1285, 2005.

[108] S. Ashwal, B. Holshouser, K. Tong et al., “Proton spectroscopy detected myoinositol in children with traumatic brain injury,” *Pediatric Research*, vol. 56, no. 4, pp. 630–638, 2004.

[109] S. Ashwal, B. Holshouser, K. Tong et al., “Proton MR spectroscopy detected glutamate/glutamine is increased in children with traumatic brain injury,” *Journal of Neurotrauma*, vol. 21, no. 11, pp. 1539–1552, 2004.

[110] T. Babikian, M. C. Freier, S. Ashwal, M. L. Riggs, T. Burley, and B. A. Holshouser, “MR spectroscopy: predicting long-term neuropsychological outcome following pediatric TBI,” *Journal of Magnetic Resonance Imaging*, vol. 24, no. 4, pp. 801–811, 2006.

[111] G. T. Manley, R. Diaz-Arrastia, M. Brophy et al., “Common data elements for traumatic brain injury: recommendations from the biospecimens and biomarkers working group,” *Archives of Physical Medicine and Rehabilitation*, vol. 91, no. 11, pp. 1667–1672, 2010.

[112] L. J. van Eldik and M. S. Wainwright, “The Janus face of glial-derived S100B: beneficial and detrimental functions in the brain,” *Restorative Neurology and Neuroscience*, vol. 21, no. 3-4, pp. 97–108, 2003.

[113] R. P. Berger, P. D. Adelson, R. Richichi, and P. M. Kochanek, “Serum biomarkers after traumatic and hypoxemic brain injuries: insight into the biochemical response of the pediatric brain to inflicted brain injury,” *Developmental Neuroscience*, vol. 28, no. 4-5, pp. 327–335, 2006.

[114] D. Gazzolo, F. Michetti, M. Bruschettini et al., “Pediatric concentrations of S100B protein in blood: age- and sex-related changes,” *Clinical Chemistry*, vol. 49, no. 6, part 1, pp. 967–970, 2003.

[115] R. P. Berger, S. R. Beers, R. Richichi, D. Wiesman, and P. D. Adelson, “Serum biomarker concentrations and outcome after pediatric traumatic brain injury,” *Journal of Neurotrauma*, vol. 24, no. 12, pp. 1793–1801, 2007.

[116] D. G. Spinella, “Biomarkers in clinical drug development: realizing the promise,” *Biomarkers in Medicine*, vol. 3, no. 6, pp. 667–669, 2009.

[117] R. P. Berger, “The use of serum biomarkers to predict outcome after traumatic brain injury in adults and children,” *Journal of Head Trauma Rehabilitation*, vol. 21, no. 4, pp. 315–333, 2006.

[118] P. C. Spinella, T. Dominguez, H. R. Drott et al., “S-100β protein-serum levels in healthy children and its association with outcome in pediatric traumatic brain injury,” *Critical Care Medicine*, vol. 31, no. 3, pp. 939–945, 2003.

[119] R. G. M. Jackson, G. S. Samra, J. Radcliffe, G. H. Clark, and C. P. Price, “The early fall in levels of S-100β in traumatic brain injury,” *Clinical Chemistry and Laboratory Medicine*, vol. 38, no. 11, pp. 1165–1167, 2000.
[120] R. G. Jacks and G. S. Samra, “Differences in the release of S100 protein during cardiopulmonary bypass (multiple letters),” *Anaesthesia*, vol. 57, no. 1, pp. 91–92, 2002.

[121] J. R. de Kruijk, P. Leffers, P. P. Menheere, S. Meerhoff, and A. Twijnstra, “S-100B and neuron-specific enolase in serum of mild traumatic brain injury patients. A comparison with health controls,” *Acta Neurologica Scandinavica*, vol. 103, no. 3, pp. 173–179, 2001.

[122] I. M. Skogseid, H. K. Nordby, P. Urdal, E. Paus, and F. Lilleaas, “Increased serum creatine kinase BB and neuron specific enolase following head injury indicates brain damage,” *Acta Neurochirurgica*, vol. 115, no. 3-4, pp. 106–111, 1992.

[123] B. G. Carter and W. Butt, “A prospective study of outcome predictors after severe brain injury in children,” *Intensive Care Medicine*, vol. 31, no. 6, pp. 840–845, 2005.

[124] A. A. Topjian, R. Lin, M. C. Morris et al., “Neuron-specific enolase and S-100B are associated with neurologic outcome after pediatric cardiac arrest,” *Pediatric Critical Care Medicine*, vol. 10, no. 4, pp. 479–490, 2009.

[125] L. E. Pelinka, A. Kroepfl, R. Schmidhammer et al., “Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma,” *The Journal of Trauma*, vol. 57, no. 5, pp. 1006–1012, 2004.

[126] D. D. Fraser, T. E. Close, K. L. Rose et al., “Severe traumatic brain injury in children elevates glial fibrillary acidic protein in cerebrospinal fluid and serum,” *Pediatric Critical Care Medicine*, vol. 12, no. 3, pp. 319–324, 2011.

[127] J. Whyte, J. Vasterling, and G. T. Manley, “Common data elements for research on traumatic brain injury and psychological health: current status and future development,” *Archives of Physical Medicine and Rehabilitation*, vol. 91, no. 11, pp. 1692–1696, 2010.

[128] R. P. Berger, S. R. Beers, L. Papa, and M. Bell, “Common data elements for pediatric traumatic brain injury: recommendations from the biospecimens and biomarkers workgroup,” *Journal of Neurotrauma*, vol. 29, no. 4, pp. 672–677, 2012.